Atlas of AIDS pp 295-315 | Cite as

Rationale and Strategies for Antiretroviral Therapy in HIV-1 Infection

  • Donna Mildvan

Keywords

Viral Load Human Immunodeficiency Virus Type Human Immunodefi Ciency Virus High Baseline Viral Load Opportunistic Infection Prophylaxis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fauci AS: Multifactorial nature of human immunodeficiency virus disease: Implications for therapy. Science 1993, 262:1011–1018.PubMedCrossRefGoogle Scholar
  2. 2.
    Holodny M, Katzenstein DA, Sengupta S, et al.: Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991, 163:862–866.CrossRefGoogle Scholar
  3. 3.
    Kievits T, van Gemen B, van Strijp D, et al.: NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991, 35:273–286.PubMedCrossRefGoogle Scholar
  4. 4.
    Cao Y, Ho DD, Todd J, et al.: Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses 1995, 11:353–361.PubMedCrossRefGoogle Scholar
  5. 5.
    Saag MS, Holodny M, Kuritzkes DR, et al.: HIV viral load markers in clinical practice. Nature Med 1996, 2:625–629.PubMedCrossRefGoogle Scholar
  6. 6.
    Mellors J, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–270.PubMedCrossRefGoogle Scholar
  7. 7.
    Mellors J, Kingsley LA, Rinaldo CR Jr, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573–579.PubMedCrossRefGoogle Scholar
  8. 8.
    O’Brien WA, Hartigan PM, Martin D, et al.: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996, 334:426–431.PubMedCrossRefGoogle Scholar
  9. 9.
    Coombs RW, Welles SL, Hooper C, et al.: Association of plasma human immunodeficiency virus type-1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996, in press.Google Scholar
  10. 10.
    Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117–122.PubMedCrossRefGoogle Scholar
  11. 11.
    Ho DD, Neumann AU, Perelson AS, et al.: Rapid turnover of plasma virions and CD4+ lymphocytes in HIV-1 infection. Nature 1995, 373:123–126.PubMedCrossRefGoogle Scholar
  12. 12.
    Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582–1586.PubMedCrossRefGoogle Scholar
  13. 13.
    US Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47 (RR-5): 42–82., Available at: http://www.hivatis.org/guide-lines/adult. Update, January 28, 2000
  14. 14.
    Cao Y, Qin L, Zhang L, et al.: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Eng J Med 1995, 332(4):201–208.CrossRefGoogle Scholar
  15. 15.
    Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Eng J Med 1995, 332(4):209–216.CrossRefGoogle Scholar
  16. 16.
    Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-fetal transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994, 331:1173–1180.PubMedCrossRefGoogle Scholar
  17. 17.
    Guay LA, Musoke P, Fleming T, et al.: Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999, 354:795–802.PubMedGoogle Scholar
  18. 18.
    Kinloch-de Loes S, Hirschel BJ, Hoen B, et al.: Zidovudine versus placebo in primary HIV infection: A randomized study. N Engl J Med 1995, 333:408–413.CrossRefGoogle Scholar
  19. 19.
    Rosenberg, ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1 specific CD+4 T cell responses Associated with control of viremia. Science 1997, 278:1447–1450.PubMedCrossRefGoogle Scholar
  20. 20.
    Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in healthcare workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997, 337:1485–1490.PubMedCrossRefGoogle Scholar
  21. 21.
    Mildvan D, Berge P, Starrett S, et al.: Prophylactic zalcitabine and interferon-α for a large-bore needlestick exposure to human immunodeficiency virus. J Acquir Immune Defic Syndr 1994, 7:416–417.PubMedGoogle Scholar
  22. 22.
    Centers for Disease Control and Prevention. Public Health Service guidelines for the management of healthcare worker exposures to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 1998, 47 (RR-7): 1–28.Google Scholar
  23. 23.
    Carpenter CCJ, Cooper DA, Fischl MA, et al.: Antiretroviral therapy in adults; updated recommendations of the International AIDS Society—USA Panel. JAMA 2000, 283:381–390.PubMedCrossRefGoogle Scholar
  24. 24.
    Friedland GH, Williams, A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13(suppl 1):S61-S72.PubMedGoogle Scholar
  25. 25.
    Mildvan D, Machado SG, Willets I, Grossberg SE: Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet 1992, 339:453–456.PubMedCrossRefGoogle Scholar
  26. 26.
    Mildvan D, Ruprecht R, Krown S, Pettinelli C: Application of the combination index method in the design of a clinical antiretroviral trial: ACTG 068. J Acquir Immune Defic Syndr 1990, 3(suppl 2):S111-S113.PubMedGoogle Scholar
  27. 27.
    Mildvan D, Bassiakos Y, Zucker ML, et al.: Synergy, activity, and tolerabili-ty of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068. Antiviral Ther 1996, 1:77–88.Google Scholar
  28. 28.
    Gao WY, Shirasaka T, Johns DG, et al.: Differential phosphorylation of azi-dothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993, 91(5):2326–2333.PubMedCrossRefGoogle Scholar
  29. 29.
    Shirasaka T, Gao WY, Kojima E, Mitsuya H: Anti-HIV activity of dideoxynu-cleosides in human resting and activated peripheral blood mononuclear cells [abstract Q149]. J Cell Biochem 1993, S17E.Google Scholar
  30. 30.
    Pollard RB, Peterson D, Hardy D, et al.: Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3. J Acquir Immune Defic Syndr 1999, 22:39–48.PubMedCrossRefGoogle Scholar
  31. 31.
    Schuurman R, Nijhuis M, van Leeuwen R, et al.: Rapid changes in human immunodeficiency type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411–1419.PubMedCrossRefGoogle Scholar
  32. 32.
    Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696–699.PubMedCrossRefGoogle Scholar
  33. 33.
    Eron J J, Benoit SL, Jemsek J, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995, 333:1662–1669.PubMedCrossRefGoogle Scholar
  34. 34.
    Haubrich R, Lalezari J, Follansbee SE, et al.: Improved survival and reduced clinical progression in HIV-infected patients with advance disease treated with saquinavir plus zalcitabine. Antivir Ther 1998, 3:33–42.Google Scholar
  35. 35.
    Collier AC, Coombs RW, Schoenfeld DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 1996, 334:1011–1017.PubMedCrossRefGoogle Scholar
  36. 36.
    Emini EA: HIV-1 protease inhibitors [abstract LB7]. Presented at the Third Conference on Retroviruses and Opportunistic Infections. Washington, DC, 1996.Google Scholar
  37. 37.
    Gulick RM, Mellors J, Havlir D, et al.: Potent and sustained antiretroviral activity of indinavir (IDV), zidovudine (ZDV) and lamivudine (3TC) [abstract Th.B.931]. Presented at the 11th International Conference on AIDS. Vancouver, BC, 1996.Google Scholar
  38. 38.
    Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N EnglJ Med 1997, 337:734–739.CrossRefGoogle Scholar
  39. 39.
    Green S, Para MF, Daly PW, et al.: Interim analysis of plasma viral burden reductions and CD4 increases in HIV-1 infected patients with Rescriptor plus Retrovir plus Epivir. 12th World AIDS Conference, Geneva, June 1998, Abstract 129/12219.Google Scholar
  40. 40.
    Clendenin N, Quart B, Anderson R, et al.: Analysis of long-term virologic data from the Viracept (nelfinavir) 511 trial using 3 HIV-RNA assays. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1998, Abstract 372.Google Scholar
  41. 41.
    Powderly WG, Tebas P: Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999,13 (suppl 1):S41-S48.PubMedCrossRefGoogle Scholar
  42. 42.
    Goodgame J, Hanson C, Vafidis D, Stein A, et al.: Amprenavir/3TC/ZDV is durable and superior to 3TC/ZDV in HIV-infected antiretroviral naïve subjects through 48 weeks. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 1999, Abstract 509.Google Scholar
  43. 43.
    Flexner C:HIV-protease inhibitors. N Engl J Med 1998, 338:1281–1292.PubMedCrossRefGoogle Scholar
  44. 44.
    Deeks SG, Hecht FM, Swanson M et al.: HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-F43.PubMedCrossRefGoogle Scholar
  45. 45.
    Durant P, Clevenbergh P, Halfon P, et al.: Drug-resistant genotyping in HIV-1 therapy: the V1RADAPT randomized controlled trial. Lancet 1999, 353:2195–2199.PubMedCrossRefGoogle Scholar
  46. 46.
    Hirsch MS, Conway B, D’Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society—USA Panel. JAMA 1998, 279:1984–1991.PubMedCrossRefGoogle Scholar
  47. 47.
    Lo JC, Mulligan K, Tai VW, Algren H, et al.: “Buffalo hump” in men with HIV-1 infection. Lancet 1998, 351:867–870.PubMedCrossRefGoogle Scholar
  48. 48.
    Miller KD, Jones E, Yanovski JA, et al.: Visceral abdominal fat accumulation associated with the use of indinavir. Lancet 1998, 351:871–875.PubMedCrossRefGoogle Scholar
  49. 49.
    Carr A, Samaras K, Thorisdottir A, et al Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipi-demia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093–2099.PubMedCrossRefGoogle Scholar
  50. 50.
    Engelson ES, Kotler, DP, Tan Y, et al.: Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am J Clin Nutr 1999, 69:1162–1169.PubMedGoogle Scholar
  51. 51.
    Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates * with the clinical state of the infected individual. J Clin Invest 1991, 87:1462–1466.PubMedCrossRefGoogle Scholar
  52. 52.
    Jacobson JM, Greenspan JS, Spritzler J, et al.: Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997, 336:1487–1493.PubMedCrossRefGoogle Scholar
  53. 53.
    Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Eng J Med 1995, 332(9):567–575.CrossRefGoogle Scholar
  54. 54.
    Lori F, Jessen H, Lieberman J, et al.: Treatment of human immunodeficiency virus infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and limited viral reservoir. J Infect Dis 1999, 180:1827–1832.PubMedCrossRefGoogle Scholar
  55. 55.
    Giorgi JV, Ho HN, Hirji I, et al.: CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: Development of HLA-DR+ CD38” CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis 1994, 170:775–781.PubMedCrossRefGoogle Scholar
  56. 56.
    Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HlV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321–329.PubMedCrossRefGoogle Scholar
  57. 57.
    Li TS, Tubiana R, Katlama C, et al.: Long lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998, 351:1682–1686.PubMedCrossRefGoogle Scholar
  58. 58.
    Lederman MM, Connick E, Landay A, et al.: Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70 –79.PubMedCrossRefGoogle Scholar
  59. 59.
    Connick E, Lederman MM, Kotzin B, et al.: Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologie response. J Infect Dis 2000, 181:358–363.PubMedCrossRefGoogle Scholar
  60. 60.
    Paul S, Gilbert HM, Ziecheck W, et al.: The impact of potent antiretroviral therapy on the characteristics of hospitalized patients with HIV infection. AIDS 1999, 13:415–418.PubMedCrossRefGoogle Scholar
  61. 61.
    Sepkowitz KA. Effect of HAART on natural history of IADS-related opportunistic disorders [comment]. Lancet 1998, 351:228–230.PubMedCrossRefGoogle Scholar
  62. 62.
    Centers for Disease Control and Prevention. US AIDS incidence, 1985–1998. Available at: http://www.cdc.gov/hiv/graphics/surveill.htm, January 18, 2000.
  63. 63.
    Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194–1199.PubMedCrossRefGoogle Scholar
  64. 64.
    Ortiz GM, Nixon DF, Trkola A, et al.: HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999, 104:R13-R18.PubMedCrossRefGoogle Scholar
  65. 65.
    Lisziewicz J, Rosenberg E, Lieberman J, et al.: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999, 340:1683–1684.PubMedCrossRefGoogle Scholar

Selected Bibliography

  1. Chiasson MA, Berenson L, Li W, et al.: Declining HIV/AIDS mortality in New York City. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 21:59–64.CrossRefGoogle Scholar
  2. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–1300.PubMedCrossRefGoogle Scholar
  3. Friedland GH, Williams A: Attaining higher goals in HIV treatment: the central importance of adherence. AIDS 1999, 13 (suppl 1):S61-S72.PubMedGoogle Scholar
  4. Gao WY, Shirasaka T, Johns DG, et al.: Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993, 91(5):2326–2333.PubMedCrossRefGoogle Scholar
  5. Kaplan JE, Hanson D, Dworkin MS, et al.: Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 2000, 30(S1):S5-S14.PubMedCrossRefGoogle Scholar
  6. Kaufman D, Pantaleo G, Sudre P, et al.: CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet 1998, 351:723–724.CrossRefGoogle Scholar
  7. Kovacs JA, Baseler M, Dewar RJ, et al.: Increases in CD4+ T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. N Eng J Med 1995, 332(9):567–575.CrossRefGoogle Scholar
  8. Larder BA, Kemp SD, Harrigan PR: Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995, 269:696–699.PubMedCrossRefGoogle Scholar
  9. Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40–47.PubMedCrossRefGoogle Scholar
  10. Mellors J, Rinaldo CR Jr, Gupta P, et al.: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167–270.PubMedCrossRefGoogle Scholar
  11. Mildvan D, Landay A, DeGruttola V, et al.: An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 1997, 24:764–774.PubMedCrossRefGoogle Scholar
  12. Perelson AS, Neumann AU, Markowitz M, et al.: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996, 271:1582–1586.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Donna Mildvan

There are no affiliations available

Personalised recommendations